Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

Cited by (1,003)

Items 101–200 of 1,003

1. Stage IV Colorectal Cancer Management and Treatment
   Oscar Hernandez Dominguez, Sümeyye Yılmaz, Scott R. Steele · 2023 · Journal of Clinical Medicine
2. Optimizing immunotherapy for colorectal cancer
   Ganesh, Karuna · 2022 · Nature Reviews Gastroenterology & Hepatology
3. Co-cultures of colon cancer cells and cancer-associated fibroblasts recapitulate the aggressive features of mesenchymal-like colon cancer
   Esther Strating, Mathijs P. Verhagen, G. Emerens Wensink, Ester Dünnebach, Liza A. Wijler, Itziar Aranguren, Alberto Sanchez De la Cruz, Niek A. Peters, Joris H. Hageman, Mirjam C. van der Net et al. · 2023 · Frontiers in Immunology
4. Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches
   Yaxian Wang, Xinyang Zhong, Xuefeng He, Zijuan Hu, Huixia Huang, Jiayu Chen, Keji Chen, Senlin Zhao, Ping Wei, Dawei Li · 2023 · Journal of Experimental & Clinical Cancer Research
5. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
   Miguel García-Pardo, Maisam Makarem, Janice J.N. Li, Deirdre Kelly, Natasha B. Leighl · 2022 · British Journal of Cancer
6. Neutrophils in the era of immune checkpoint blockade
   Julien Faget, Solange Peters, Xavier Quantin, Etienne Meylan, Nathalie Bonnefoy · 2021 · Journal for ImmunoTherapy of Cancer
7. The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
   Francesca Corti, Sara Lonardi, Rossana Intini, Massimiliano Salati, Elisabetta Fenocchio, Carmen Belli, Beatrice Borelli, Marta Brambilla, Alessandra Anna Prete, Virginia Quarà et al. · 2021 · European Journal of Cancer
8. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
   Noura J. Choudhury, Antonio Marra, Jane Sze Yin Sui, Jessica R. Flynn, Soo‐Ryum Yang, Christina J. Falcon, Pier Selenica, Adam Jacob Schoenfeld, Natasha Rekhtman, Daniel Richard Gomez et al. · 2022 · Journal of Thoracic Oncology
9. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
   Quincy Siu-Chung Chu, Federica Perrone, Laurent Greillier, Wei Tu, Maria Carmela Piccirillo, Federica Grosso, Giuseppe Lo Russo, Marie Florescu, Manlio Mencoboni, Alessandro Morabito et al. · 2023 · The Lancet
10. Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy
    Shannon N Geels, Alexander Moshensky, Rachel S Sousa, Claire Murat, Matias Alberto Bustos, Benjamin L. Walker, Rima Singh, Stacey N. Harbour, Giselle Gutierrez, Michael Hwang et al. · 2024 · Cancer Cell
11. Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients
    Yu Feng, Wenjuan Ma, Yupeng Zang, Yanying Guo, Young Li, Yixuan Zhang, Xuan Dong, Yi Liu, Xiaojuan Zhan, Zhizhong Pan et al. · 2024 · Nature Communications
12. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
    Marion Thibaudin, Jean-David Fumet, Benoist Chibaudel, Jaafar Bennouna, Christophe Borg, Jérôme Martin-Babau, Romain Cohen, Marianne Fonck, Julien Taı̈eb, Emeric Limagne et al. · 2023 · Nature Medicine
13. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
    Maurice Stephan Michel, Leonard Kaps, Annett Maderer, Peter R. Galle, Markus Hermann Moehler · 2021 · Cancers
14. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
    Margherita Ambrosini, Benoı̂t Rousseau, Paolo Manca, Oliver Artz, Aurélien Marabelle, Thierry André, G. Maddalena, Giacomo Mazzoli, R. Intini, Romain Cohen et al. · 2024 · Annals of Oncology
15. Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application
    Echle, A., Ghaffari Laleh, N., Quirke, P., Grabsch, H.I., Muti, H.S., Saldanha, O.L., Brockmoeller, S.F., van den Brandt, P.A., Hutchins, G.G.A., Richman, S.D. et al. · 2022 · ESMO Open
16. The role of biomarkers in personalized immunotherapy
    Sankar, Kamya, Ye, Jing Christine, Li, Zihai, Zheng, Lei, Song, Wenru, Hu-Lieskovan, Siwen · 2022 · Biomarker Research
17. Systemic treatment for metastatic colorectal cancer
    Wattana Leowattana, Pathomthep Leowattana, Tawithep Leowattana · 2023 · World Journal of Gastroenterology
18. A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
    Chida, Keigo, Kawazoe, Akihito, Kawazu, Masahito, Suzuki, Toshihiro, Nakamura, Yoshiaki, Nakatsura, Tetsuya, Kuwata, Takeshi, Ueno, Toshihide, Kuboki, Yasutoshi, Kotani, Daisuke et al. · 2021 · Clinical Cancer Research
19. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
    Katrin Pansy, Barbara Uhl, Jelena Krstić, Marta Szmyra, Karoline Fechter, Ana Santiso, Lea Thüminger, Hildegard Greinix, Julia Kargl, Katharina Theresa Prochazka et al. · 2021 · International Journal of Molecular Sciences
20. Landscape of KRAS G12C , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS -Mutated Cancers
    Mohamed E. Salem, Sherif Mohamed El-Refai, Wei Sha, Alberto Puccini, Axel Grothey, Thomas J. George, Jimmy J. Hwang, Bert H. O’Neil, Alexander S. Barrett, Kunal C. Kadakia et al. · 2022 · JCO Precision Oncology
21. Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
    Núria Mulet-Margalef, Jenniffer Linares, Jordi Badia-Ramentol, Mireya Jimeno, Carolina Sanz, José Luis Manzano Mozo, Alexandre Calon · 2023 · Cancers
22. Cancer cell-intrinsic mechanisms driving acquired immune tolerance
    Ehsan Ghorani, Charles Swanton, Sergio A. Quezada · 2023 · Immunity
23. Colorectal Cancer in Younger Adults
    Pooja Dharwadkar, Timothy A. Zaki, Caitlin C. Murphy · 2022 · Hematology/Oncology Clinics of North America
24. Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer
    Amit Dey, Abhijit Mitra, Surajit Pathak, Suhanya Veronica Prasad, Alexander Sun-Zhang, Hong Zhang, Xiao‐Feng Sun, Antara Banerjee · 2023 · Technology in Cancer Research & Treatment
25. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
    Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, Giorgio Frega, Andrea Palloni, Simona Tavolari, Giovanni Brandi · 2021 · Frontiers in Oncology
26. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer
    John H. Strickler, Takayuki Yoshino, Rondell Patrell Graham, Salvatore Siena, Tanios Bekaii‐Saab · 2022 · JAMA Oncology
27. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
    Sonali M. Smith, KERRI WACHTER, Howard A. Burris, Richard L. Schilsky, Daniel J. George, Douglas E. Peterson, Melissa Lynne Johnson, Merry Jennifer Markham, Kathryn Finch Mileham, Muhammad Shaalan Beg et al. · 2021 · Journal of Clinical Oncology
28. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
    Yaping Chen, Xiao Zheng, Changping Wu · 2021 · Frontiers in Immunology
29. The Role of Immunotherapy in Pancreatic Cancer
    Reetu Mukherji, Dipanjan Debnath, Marion L. Hartley, Marcus Smith Noel · 2022 · Current Oncology
30. Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164
    Dung Thi Le, Luis Alberto Diaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan et al. · 2023 · European Journal of Cancer
31. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort
    Lina Hountondji, Christophe Ferreira De Matos, Fanny Lebossé, Xavier Quantin, Candice Lesage, Pascale Palassin, Valérian Rivet, Stéphanie Faure, Georges‐Philippe Pageaux, Eric Assénat et al. · 2023 · JHEP Reports
32. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort
    Julien Taı̈eb, Lina Sayah, Kathrin Heinrich, Volker Kunzmann, Alice Boilève, Geert A. Cirkel, Sara Lonardi, Benoist Chibaudel, Anthony Turpin, Tamar Beller et al. · 2023 · European Journal of Cancer
33. Neoadjuvant treatment of colorectal cancer: comprehensive review
    Henry George Smith, Per Johan Nilsson, Benjamin D. Shogan, Deena Pravin Harji, Maria Antonietta Gambacorta, Ângela Romano, Andreas Brandl, Camilla Qvortrup · 2024 · BJS Open
34. DNA mismatch repair proteins: scientific update and practical guide
    Adrian Calvin Bateman · 2021 · Journal of Clinical Pathology
35. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer
    Chaofan Liu, Xi Wang, Wan Qin, Jingyao Tu, Chunya Li, Weiheng Zhao, Li Ma, Bo Liu, Hong Qiu, Xianglin Yuan · 2023 · 癌症：英文版
36. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
    Christopher J.M. Williams, Allyson Moraig Peddle, Pashtoon Murtaza Kasi, Jenny F. Seligmann, Campbell S.D. Roxburgh, Gary Middleton, Sabine Tejpar · 2024 · Nature Reviews Clinical Oncology
37. The landscape of cancer research and cancer care in China
    Zhihao Lu, Yang Chen, Dan Liu, Xi Jiao, Chang Xin Liu, Yakun Wang, Zizhen Zhang, Keren Jia, Jifang Gong, Zhimin Yang et al. · 2023 · Nature Medicine
38. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
    Xinan Wang, Giuseppe Lamberti, Alessandro Di Federico, Joao V. Alessi, Roberto Ferrara, M.L. Sholl, Mark Magdi Awad, Natalie I. Vokes, Biagio Ricciuti · 2024 · Annals of Oncology
39. Unveiling the role of KRAS in tumor immune microenvironment
    Miao Xu, Xing Zhao, Ti Wen, Xiujuan Qu · 2024 · Biomedicine & Pharmacotherapy
40. <i>BRAF</i> -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
    Ciombor, Kristen K., Strickler, John H., Bekaii-Saab, Tanios S., Yaeger, Rona · 2022 · Journal of Clinical Oncology
41. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer
    Qi Lv, Yishu Zhang, Wen Gao, Juan Wang, Yaowen Hu, Hongqiong Yang, Ying Xie, Yingshan Lv, Heyuan Zhang, Dapeng Wu et al. · 2024 · Pharmacological Research
42. Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
    Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taı̈eb, Filippo Pietrantonio · 2025 · Nature Reviews Clinical Oncology
43. Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies
    Reshmi Nair, Veena Somasundaram, Anshu Kuriakose, Shiv Ram Krishn, David Raben, Rachel L. Salazar, Pradip Nair · 2025 · Frontiers in Immunology
44. Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments
    Qian Wang, Fangwei Yuan, Xianglin Zuo, Ming Li · 2025 · Cell Death Discovery
45. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer
    Yusuke Kinugasa, Keisuke Uehara, Kensei Yamaguchi, Yutaka Saito, Keiko Nemoto Murofushi, Tamotsu Sugai, Megumi Ishiguro, Soichiro Ishihara, Hideki Ueno, Shiro Oka et al. · 2025 · International Journal of Clinical Oncology
46. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone
    Bengt L. G. Glimelius, Sebastian Stintzing, John Lindsay Marshall, Takayuki Yoshino, Aimery de Gramont · 2021 · Cancer Treatment Reviews
47. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
    Miguel López de Rodas, María Villalba-Esparza, Miguel F. Sanmamed, Lieping Chen, David L. Rimm, Kurt Alex Schalper · 2025 · Nature Reviews Clinical Oncology
48. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
    Yohann Loriot, Aurélien Marabelle, Jean‐Philippe Guégan, François‐Xavier Danlos, Benjamin Besse, Nathalie Chaput, Christophe Massard, David Planchard, Caroline Robert, Caroline Even et al. · 2021 · Annals of Oncology
49. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer
    An Huang, Yong Yang, Jing-Yi Shi, Yukun Li, Jing‐Xuan Xu, Yu Qing Cheng, Jin Gu · 2021 · World Journal of Gastrointestinal Surgery
50. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer
    Song Li, Yu Hao, Chunjie Wang, Yikai Han, Yujie Zhu, Liangzhu Feng, Liyan Miao, Zhuang Liu · 2022 · Journal of Controlled Release
51. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
    Dominik Paul Modest, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Alexander Otto König, Ludwig Fischer von Weikersthal, Karel Caca, Albrecht Kretzschmar, Eray Goekkurt et al. · 2021 · Journal of Clinical Oncology
52. Advances in the management of peritoneal malignancies
    Vahan Képénékian, Aditi Bhatt, Julien Péron, Mohammad S. Alyami, Nazim Benzerdjeb, Naoual Bakrin, Claire Falandry, Guillaume Passot, Pascal Rousset, Olivier Gléhen · 2022 · Nature Reviews Clinical Oncology
53. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer
    Takayuki Yoshino, Andrès M.R. Cervantes, Hideaki Bando, Erika Martinelli, Eiji Oki, Rui‐Hua Xu, Nadia Ayu Mulansari, K. Govind Babu, M.A. Lee, Cheng Tan et al. · 2023 · ESMO Open
54. Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy
    Chuan Liu, Jindong Xie, Bo Lin, Weihong Tian, Yifan Wu, Xin Shan, Libing Hong, Xin Li, Lulu Liu, Yuzhi Jin et al. · 2024 · Advanced Science
55. Strategies to tackle RAS-mutated metastatic colorectal cancer
    Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D.A., Pani, A., Scaglione, F., Siena, S., Sartore-Bianchi, A. · 2021 · ESMO Open
56. The Inherited and Familial Component of Early-Onset Colorectal Cancer
    María Daca-Álvarez, Isabel Quintana, Mariona Terradas, Pilar Mur, Francesc Balaguer, Laura Valle · 2021 · Cells
57. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study
    Pedro Luiz Serrano Usón, Douglas L. Riegert‐Johnson, Lisa Boardman, John B. Kisiel, Luke J. Mountjoy, Neej J. Patel, Blanca Lizaola‐Mayo, Mitesh J. Borad, Daniel H. Ahn, Mohamad Bassam Sonbol et al. · 2021 · Clinical Gastroenterology and Hepatology
58. Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines
    Vladimir Roudko, Cansu Cimen Bozkus, Benjamin D. Greenbaum, Aimee Lee Lucas, Robert M. Samstein, Nina Bhardwaj · 2021 · Frontiers in Immunology
59. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
    Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, Gennaro Palmiotti · 2022 · Expert Review of Gastroenterology & Hepatology
60. Facts and Hopes in Immunotherapy of Pancreatic Cancer
    Bruno Bockorny, Joseph Elan Grossman, Manuel M. Hidalgo · 2022 · Clinical Cancer Research
61. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update
    Feng Wang, Gong Chen, Zhen Zhang, Ying Yuan, Yi Wang, Yuanhong Gao, Weiqi Sheng, Zixian Wang, Xinxiang Li, Xianglin Yuan et al. · 2024 · 癌症：英文版
62. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity
    Yimeng Ren, Yun Qian, Luoyan Ai, Yile Xie, Yaqi Gao, Ziyan Zhuang, Jinxian Chen, Yingxuan Chen, Jing‐Yuan Fang · 2021 · Nature Communications
63. PD-L1: expression regulation
    Yu-Jie Zhou, Guoli Li, Jiyin Wang, Mengyuan Liu, Zihan Wang, Yu Song, Xulong Zhang, Xi Wang · 2023 · Blood Science
64. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
    Guillaume Mestrallet, Matthew Brown, Cansu Cimen Bozkus, Nina Bhardwaj · 2023 · Frontiers in Immunology
65. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer
    Eric Xueyu Chen, Jonathan M. Loree, Emma Titmuss, Derek J. Jonker, Hagen Fritz Kennecke, Scott R. Berry, Felix Couture, Chaudharry E. Ahmad, John R. Goffin, Petr Kavan et al. · 2023 · JAMA Network Open
66. Digestive cancers: mechanisms, therapeutics and management
    Tianzuo Zhan, Johannes Betge, Nadine Schulte, Lena Dreikhausen, Michael Hirth, Moying Li, Philip Weidner, Antonia Leipertz, Andreas Teufel, Matthias P A Ebert · 2025 · Signal Transduction and Targeted Therapy
67. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
    Jiaojiao Ni, Zizhen Zhang, Ming-jie Ge, Jingyu Chen, Wei Zhuo · 2022 · Acta Pharmacologica Sinica
68. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review
    Wei-Jian Mei, Mi Mi, Jing Qian, Nan Xiao, Ying Yuan, Peirong Ding · 2022 · Frontiers in Immunology
69. Immunotherapy and immunoevasion of colorectal cancer
    Mohammad Al Zein, Mona Boukhdoud, Hadi Shammaa, Hadi Mouslem, Lemir Majed El Ayoubi, Rabah Iratni, Khodr Issa, Maha Youssef Khachab, Hazem I. Assi, Amirhossein Sahebkar et al. · 2023 · Drug Discovery Today
70. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
    Junko Tanizaki, Kan Yonemori, Kohei Akiyoshi, Hironobu Minami, Hiroki Ueda, Yuichi Takiguchi, Yuji Miura, Yoshihiko Segawa, Shinʼ ichi Takahashi, Y. Iwamoto et al. · 2021 · Annals of Oncology
71. Weakly supervised annotation‐free cancer detection and prediction of genotype in routine histopathology
    Peter L. Schrammen, Narmin Ghaffari Laleh, Amelie Echle, Daniel Truhn, Volkmar Schulz, Titus J. Brinker, Hermann Brenner, Jenny C. Chang-Claude, Elizabeth Alwers, Alexander Brobeil et al. · 2021 · The Journal of Pathology
72. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
    Wantao Wu, Yihan Liu, Shan Zeng, Ying Han, Hong Shen · 2021 · Journal of Hematology & Oncology
73. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
    Xingyu Chen, Lixiang Feng, Yujing Huang, Yi Wu, Na Xie · 2022 · Cancers
74. Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
    Xiang Chen, Lingjuan Chen, Xiaofei Peng, Ling Deng, Yan Wang, Jiu-Jiang Li, Dongli Guo, Xiaohua Niu · 2023 · Translational Oncology
75. Spatial transcriptomics in cancer research and potential clinical impact: a narrative review
    Michael A. Cilento, Christopher J. Sweeney, Lisa M. Butler · 2024 · Journal of Cancer Research and Clinical Oncology
76. Immune organoids: from tumor modeling to precision oncology
    Vinh A Dao, Kanako Yuki, Yuan‐Hung Lo, Michitaka Nakano, Calvin Jay Kuo · 2022 · Trends in cancer
77. Hereditary cancer syndromes
    Евгений Наумович Имянитов, Ekatherina Sh. Kuligina, Анна Петровна Соколенко, Evgeny N. Suspitsin, Grigoriy A. Yanus, Aglaya G. Iyevleva, Alexandr O. Ivantsov, Светлана Николаевна Алексахина · 2023 · World Journal of Clinical Oncology
78. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies
    Wei Ming Shi, Yin Wang, Yuehui Zhao, Justin J. Kim, Haoyan Li, Chenling Meng, Feiyu Chen, Jie Zhang, Duncan H. F. Mak, Vivien Van et al. · 2023 · Science Translational Medicine
79. The strategies to cure cancer patients by eradicating cancer stem-like cells
    Yansui Mai, Jiyan Su, Chuan Yang, Chenglai Xia, Liwu Fu · 2023 · Molecular Cancer
80. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
    Heinz‐Josef Lenz, Aparna R. Parikh, David Robert Spigel, Allen Lee Cohn, Takayuki Yoshino, Mark D. Kochenderfer, Elena Élez, Spencer H. Shao, Dustin A. Deming, Regan C. Holdridge et al. · 2024 · Journal for ImmunoTherapy of Cancer
81. Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
    Suying Yan, Wanting Wang, Zhiqiang Feng, Jun Xue, Weizheng Liang, Xueliang Wu, Zhiquan Tan, Xipeng Zhang, Shuai Zhang, Xichuan Li et al. · 2024 · Frontiers in Immunology
82. Upregulation of HSPA1A/HSPA1B/HSPA7 and Downregulation of HSPA9 Were Related to Poor Survival in Colon Cancer
    Yufeng Guan, Xianjun Zhu, Junjie Liang, Min Wei, Shan Huang, Xiaofen Pan · 2021 · Frontiers in Oncology
83. Targeted Therapy for Colorectal Cancer
    Shinichiro Sakata, David W. Larson · 2022 · Surgical Oncology Clinics of North America
84. Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives
    Rodrigo Motta, Santiago Cabezas-Camarero, Cesar Torres Mattos, Alejandro Riquelme, Ana Calle, Alejandro Figueroa, Miguel J. Sotelo · 2021 · Journal of Clinical and Translational Research
85. Distinct Mechanisms of Mismatch Repair Deficiency Delineate Two Modes of Response to PD-1 Immunotherapy in Endometrial Carcinoma
    Ryan Dz-Wei Chow, Tai Michaels, Stefania Bellone, Tobias M.P. Hartwich, Elena Bonazzoli, Akiko Iwasaki, Eric Song, Alessandro Davide Santin · 2022 · Cancer Discovery
86. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
    Mauri, Gianluca, Bonazzina, Erica, Amatu, Alessio, Tosi, Federica, Bencardino, Katia, Gori, Viviana, Massihnia, Daniela, Cipani, Tiziana, Spina, Francesco, Ghezzi, Silvia et al. · 2021 · Cancers
87. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
    Daniel C. Kreatsoulas, Chelsea M. Bolyard, Bill Xingjun Wu, Hakan Çam, Pierre Giglio, Zihai Li · 2022 · Journal of Hematology & Oncology
88. New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer
    Lu Lu, Jiahuan Dong, Yujing Liu, Yufan Qian, Guangtao Zhang, Wenjun Zhou, Aiguang Zhao, Guang Ji, Hanchen Xu · 2022 · Frontiers in Pharmacology
89. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
    Stephen L. Wang, Timothy An-thy Chan · 2025 · Cancer Cell
90. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
    Hidayati Husainy Hasbullah, Marahaini Musa · 2021 · International Journal of Molecular Sciences
91. Visual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021
    Ma, Long, Ma, Jixiang, Teng, Muzhou, Li, Yumin · 2022 · Frontiers in Immunology
92. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
    Emre Küçükköse, Balthasar A. Heesters, Julien Villaudy, André Verheem, Madalina G. Cercel, Susan van Hal, Sylvia F. Boj, Inne H.M. Borel Rinkes, Cornelis J.A. Punt, Jeanine M.L. Roodhart et al. · 2022 · Journal for ImmunoTherapy of Cancer
93. Apolipoprotein L3 enhances CD8+ T cell antitumor immunity of colorectal cancer by promoting LDHA-mediated ferroptosis
    Yang Lv, Wentao Tang, Wenju Chang, Wenju Chang, YuQiu Xu, Lin Qi, Meiling Ji, Qingyang Feng, Jianmin Xu, Guodong He · 2023 · International Journal of Biological Sciences
94. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
    Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J. Adashek · 2023 · Pharmaceuticals
95. A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer
    Acha-Sagredo, Amelia, Andrei, Pietro, Clayton, Kalum, Taggart, Emma, Antoniotti, Carlotta, Woodman, Chloé A., Afrache, Hassnae, Fourny, Constance, Armero, Maria, Moinudeen, Hafsa Kaja et al. · 2025 · Cancer Cell
96. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update
    Aristeidis E. Boukouris, Maria Theochari, Dimitra T. Stefanou, Alexandros Papalambros, Evangelos S. Felekouras, Helen J Gogas, Dimitrios C. Ziogas · 2022 · Critical Reviews in Oncology/Hematology
97. A new strategy for immunotherapy of microsatellite‐stable (MSS) ‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD ‐1/ PD‐L1 inhibitors
    Lingli Cai, Anqi Chen, Dong Tang · 2024 · Immunology
98. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis
    Naoki Hamada, Ayaka Maeda, Kaoru Takase‐Minegishi, Yohei Kirino, Yumiko Sugiyama, Ho Namkoong, Nobuyuki Horita, Ryusuke Yoshimi, Hideaki Nakajima, YCU irAE Working Group · 2021 · Frontiers in Immunology
99. The Evolving Treatment Landscape in BRAF-V600E –Mutated Metastatic Colorectal Cancer
    Josep M. Tabernero, Javier Ros, Elena Élez · 2022 · American Society of Clinical Oncology Educational Book
100. Artificial intelligence-based biomarkers for treatment decisions in oncology
     Marta Ligero, Omar S. M. El Nahhas, Mihaela D. Aldea, Jakob Nikolas Kather · 2025 · Trends in cancer